503A & 503B Compounders

Section 503A of the Federal Food, Drug, and Cosmetic Act generally covers pharmacy compounding based on valid prescriptions for individually identified patients, subject to applicable statutory conditions. Section 503B establishes a separate category for FDA-registered outsourcing facilities that may compound certain drugs without patient-specific prescriptions, subject to statutory conditions and additional FDA oversight. Their regulatory obligations differ. RCA provides consulting support to both 503A pharmacies and 503B outsourcing facilities based on their specific compliance needs.

Registered 503B outsourcing facilities are subject to applicable statutory requirements, including FDA current Good Manufacturing Practice requirements. Relevant controls can include quality oversight, procedures, documentation, facilities, manufacturing processes, and contamination control. The precise requirements depend on the facility’s activities and products. RCA helps outsourcing facilities assess compliance gaps, strengthen quality systems, and prepare for FDA inspections.

A 503B outsourcing facility should assess its quality systems, review batch and production records, evaluate aseptic processing and environmental monitoring programs where applicable, verify CAPA and deviation processes, and train employees on inspection procedures. RCA provides inspection readiness consulting, mock inspections, quality system assessments, and remediation support to help facilities identify and address compliance weaknesses.

A compounding pharmacy should carefully evaluate the agency’s findings, investigate root causes, assess the scope of each deficiency, and establish corrective actions supported by documented evidence. The response should address systemic issues and include a plan to evaluate effectiveness. RCA supports 503A and 503B organizations with regulatory response planning, compliance gap assessments, quality system remediation, and sustainable corrective action strategies.

Transitioning from 503A to 503B involves more than registering with the FDA. An organization should assess facility design, manufacturing processes, quality systems, documentation, personnel, validation needs, and applicable cGMP requirements. It must also understand the statutory conditions governing 503B operations. RCA’s consulting support can help organizations evaluate readiness, identify compliance gaps, and develop a roadmap for the transition.